ANIP vs HIK.L
ANIP: ANI Pharmaceuticals is a specialized biopharma company focused on acquiring, developing, and marketing both branded and generic prescription drugs. HIK.L: Hikma Pharmaceuticals is a global provider of generic, branded, and injectable medicines with a significant footprint in the US and MENA markets.
Side-by-side fundamentals
| Metric | ANIP | HIK.L | Edge |
|---|---|---|---|
| Price as of 2026-08-24 close | $74.17 | £16.24 | |
| Market cap as of 2026-08-25 | $1.8B | $4.7B | |
| P/E as of 2026-08-25 | 18.72 | n/a | |
| PEG as of 2026-08-25 | 1.13 | n/a | |
| Net margin | +10.0% | +12.2% | HIK.L higher |
| Gross margin | +60.8% | +43.0% | ANIP higher |
| Operating margin as of 2026-08-25 | +13.4% | n/a | |
| ROE | +17.8% | +15.6% | ANIP higher |
| ROA as of 2026-08-25 | +6.6% | n/a | |
| Debt / equity as of 2026-08-25 | 1.09 | n/a | |
| Revenue growth (YoY) as of 2026-08-25 | +37.0% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +40.8% | n/a | |
| Dividend yield as of 2026-08-25 | +0.0% | n/a | |
| Beta as of 2026-08-25 | 0.51 | n/a | |
| 1-year return as of 2026-08-24 close | -18.5% | -10.3% | HIK.L higher |
Fundamentals: market data, as of 2026-08-25. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.